Csenge Advisory Group Acquires 2,423 Shares of GSK plc (NYSE:GSK)

Csenge Advisory Group raised its holdings in GSK plc (NYSE:GSK) by 13.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,141 shares of the pharmaceutical company’s stock after acquiring an additional 2,423 shares during the period. Csenge Advisory Group’s holdings in GSK were worth $681,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Indiana Trust & Investment Management Co increased its position in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Eastern Bank acquired a new position in shares of GSK during the third quarter worth $26,000. Crews Bank & Trust bought a new position in shares of GSK in the 4th quarter valued at $26,000. ST Germain D J Co. Inc. grew its position in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares during the last quarter. Finally, Sunbelt Securities Inc. increased its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on GSK shares. Morgan Stanley started coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Down 1.0 %

Shares of NYSE:GSK opened at $36.20 on Tuesday. The business’s 50-day moving average is $34.42 and its 200-day moving average is $37.44. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The company has a market capitalization of $75.02 billion, a price-to-earnings ratio of 22.76, a P/E/G ratio of 1.42 and a beta of 0.64. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.53.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Equities research analysts predict that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be issued a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.34%. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio (DPR) is presently 93.08%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.